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Background: An inflammatory component is present in the microenvironment of most neoplastic tissues.
Inflammation and elevated C-reactive protein (CRP) are associated with poor prognosis and decreased survival in
many types of cancer.
Vitamin C has been suggested as having both a preventative and therapeutic role in a number of pathologies
when administered at much higher-than-recommended dietary allowance levels.
Since in vitro studies demonstrated inhibition of pro-inflammatory pathways by millimolar concentrations of
vitamin C, we decided to analyze the effects of high dose IVC therapy in suppression of inflammation in cancer
patients.
Methods: 45 patients with prostate cancer, breast cancer, bladder cancer, pancreatic cancer, lung cancer, thyroid
cancer, skin cancer and B-cell lymphoma were treated at the Riordan Clinic by high doses of vitamin C (7.5 g -50 g)
after standard treatments by conventional methods.
CRP and tumor markers were measured in serum or heparin-plasma as a routine analysis. In addition, serum
samples were collected before and after the IVCs for the cytokine kit tests.
Results: According to our data positive response to treatment, which was demonstrated by measurements of
C- reactive protein, was found in 75% of patients and progression of the inflammation in 25% of patients. IVC
treatments on all aggressive stage cancer patients showed the poor response of treatment.
There was correlation between tumor markers (PSA, CEA, CA27.29 and CA15-3) and changes in the levels of
C-reactive protein.
Our test of the effect of IVC on pro-inflammatory cytokines demonstrated that inflammation cytokines IL-1α,
IL-2, IL-8, TNF-α, chemokine eotaxin and CRP were reduced significantly after treatments.
Conclusions: The high dose intravenous ascorbic acid therapy affects C-reactive protein levels and
pro-inflammation cytokines in cancer patients. In our study, we found that modulation of inflammation by
IVC correlated with decreases in tumor marker levels.
In summary, our data support the hypothesis that high dose intravenous ascorbate treatments may reduce
inflammation in cancer patients. Our results suggest that further investigations into the use of IVC to reduce
inflammation in diseases where inflammation is relevant are warranted.Background
Inflammation plays a key role in tumour development,
affecting tumour proliferation, angiogenesis, metastasis,
and resistance to therapy [1-6]. Key features of cancer-
related inflammation (CRI) include leukocyte infiltration,
cytokine build-up, tissue remodelling, and angiogenesis.
Infiltrating leukocytes such as tumour associated* Correspondence: nmikirova@riordanclinic.org
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reproduction in any medium, provided the ormacrophages (TAMs), neutrophils, dendritic cells, and
lymphocytes establish an inflammatory microenviron-
ment [7] and are key components in tumours of epithe-
lial origins [8]. These leukocytes secrete pro-
inflammatory cytokines such as IL1, IL6, TNFα, TGFβ,
FGF, EGF and HGF21, as well as chemokines such as
CCL2 and CXCL8 [9]. While immune cells may repress
tumour growth in some cases [10-12], there is increasing
concern that inflammatory microenvironments caused
by infiltrating leukocytes can facilitate cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciated with poor prognosis, while the use of anti-
inflammatory agents is associated with reduced instances of
certain cancers [14,17].
Several studies indicate that inflammation is a marker of
high cancer risk and poor treatment outcome [18-22]. In
response to systemic inflammation, and in particular in re-
sponse to elevated IL-6 levels, the liver produces CRP [23],
a protein that binds to dead or dying cells to activate the
complement system. CRP can be used as a marker of sys-
temic inflammation. It correlates with disease progression
and can be used to monitor infection [18,24-27]. For ex-
ample, subjects with highly elevated CRP concentrations
(above 80 mg/L, as compared to values below 5 mg/L)
showed 3.5 times the risk for “all-cause” mortality com-
pared to other subjects [28]. There are particularly strong
negative correlations between CRP levels and cancer sur-
vival [14,24,28-38] in a wide variety of cancer types. For ex-
ample, cancer patients with highly elevated CRP showed
increased mortality by a factor of 28. Thus, CRP concentra-
tion data confirm a correlation between cancer progression
and inflammation.
Serum CRP concentrations in human subjects are,
according to one report, inversely correlated with antioxi-
dant nutrient concentrations [39]. Vitamin C (ascorbate, as-
corbic acid, AA) is a water-soluble antioxidant and essential
nutrient for immune cells and extracellular matrix produc-
tion [40,41]. These properties, as well as the correlations
between ascorbate depletion in cancer patients and progno-
sis [42], suggest that vitamin C may have a beneficial effect
on inflammation in cancer patients. Experiments by Hartel
et al. [43] indicate that 20 mM ascorbate inhibited produc-
tion of IL-6 and TNF-α in monocytes without affecting IL-
1 or IL-8 levels. For lymphocytes, the same ascorbate con-
centrations inhibited IL-2 production without affecting
TNF-α of IFN-γ levels. Ascorbate, at milli molar concentra-
tions, may also inhibit NF-κB activation in endothelial cells
[44]. NF-κB is an important transcription factor that med-
iates changes in gene expression during inflammation. The
effect may be concentration dependent, as a different study
indicated that low ascorbate doses (0.2 mM) actually
enhanced NF-κB in Jurkat T-cells [45]. Other studies show
that ascorbate inhibits TNF-α activation of NF-κB in
human cell lines in vitro in a concentration dependent fash-
ion, and can also inhibit GM-CSF, IL-3, and IL-5 produc-
tion [46].
While millimolar ascorbate concentrations are not
usually considered ‘physiological’, they can be achieved if
the vitamin is administered intravenously at high dose.
Intravenous vitamin C therapy has been used in the
treatment of cancer [47,48]. Rationales for IVC therapy
include preferential toxicity of ascorbate toward cancer
cells [49,50], potential benefits of ascorbate for immune
cells [48], and ascorbate inhibitory effect on angiogenesis[51,52]. In a study with guinea pigs, tumour growth was
significantly reduced in cases where intra-tumour ascor-
bate concentrations reached the millimolar level [53].
In addition, inflammation and oxidative stress can
cause down-regulation of immune system associated
with T cell dysfunction, which has been described in
cancer, infectious, and autoimmune diseases. In cancer
and other inflammatory conditions, the T cell receptor
(TCR) zeta chain is cleaved resulting in T-cell and Nat-
ural Killer (NK) cell inability to activate [54]. Several
studies have shown that chronic inflammation is
mandatory for the induction of an immunosuppressive
environment, due to the high concentrations of reactive
oxygen species formed by myeloid suppressor cells
[55,56]. Clinically, this occurrence is associated with
poor prognosis [57,58]. As the in vitro tissue cultures
have shown a reversal of TCR cleavage by antioxidants
[59,60], the result of treatment by ascorbic acid may
augment T-cell and NK cell immunity.
Over the course of 35 years, the Riordan Clinic has
administered IVC to cancer patients. For some of these
subjects, blood chemistry data before, during, and after
IVC treatments provide measurements of plasma ascor-
bate, CRP levels, and the levels of cancer markers such
as PSA and CEA. This manuscript details an analysis of
these clinical data to determine if a correlation exists be-
tween IVC treatments, inflammation (measured by CRP,
cytokine levels), and tumour progression (measured by
PSA, CEA and other tumour markers).
Methods
Biochemical assays and analysis
CRP concentrations in blood (serum or heparin-plasma) were
analysed using a particle-enhanced immune-turbidimetric
assay (CRP Ultra WR Reagent kit, Genzyme) according to
manufacturer’s instructions on an automated analyser
(CobasMIRA, Roche Diagnostics). The upper boundary
for the normal range was set to 1.9 mg/L.
Blood concentrations of cytokines INF-γ, IL-1, IL-2,
IL-8, TNF-α, and eotaxin were obtained using commer-
cially available cytokine array ELISA kits (Ray Biotech).
The chemiluminescent signal was imaged by the Bio-
Image system (Alpha Innotech). The antigen-antibody
spots on the image were circled by Spot Denso of
FluorChem SP software (Alpha Innotech). Serum sam-
ples from non-cancer people were used as normal
ranges. The pro-inflammatory markers from eleven
patients before and after 6 IVCs were compared.
Serum vitamin C measurements were attained as
described elsewhere [61].
Statistical analysis
The data were analysed by Systat software (Systat, Inc)
and Kaleidagraph software. Variables were presented as
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25th percentiles. Association between different factors
was assessed using linear models. Statistical significance
was accepted if the null hypothesis could be rejected
at p ≤ 0.05.
Patients and treatments
The diagnosis of patients as to their malignant disease
and status was based on the information provided to
Riordan Clinic and sent from pathologist and/or oncolo-
gist at the request of the patient.
First, patients are tested for glucose-6-phosphate de-
hydrogenase deficiency prior to treatment, as this defi-
ciency can cause hemolysis. Patients with G6PDH
deficiency were not given IVC. For eligible patients, the
Riordan IVC protocol was administered as described
elsewhere [48]. Briefly, subjects initially receive of 7.5 to
15 g ascorbate infused by slow drip in saline solution.
To ensure that patient has adequate renal function, hy-
dration and urinary voiding capacity, baseline lab tests
were performed that include a serum chemistry profile
and urinalysis. Provided these first treatments are well
tolerated, patients are given the option to continue with
25 to 50 g infusions up to three times per week.
Patients who received IVC treatment signed informed
consent. Privacy and patient anonymity guidelines were
strictly followed in gathering the data for analysis.
Data were analysed for 45 patients who went through
the Riordan IVC protocol: twenty-four with prostate can-
cer, nine with breast cancer, three each with bladder can-
cer, pancreatic cancer, and lung cancer, and one each with
thyroid cancer, skin cancer and B-cell lymphoma. Several
patients had metastasis. Treatment and additional clinical
data were obtained from medical records. Many of the
patients were treated initially by conventional way, by op-
eration, radiotherapy, and administration of hormones
and cytotoxic substances. Characteristics of subjects under
analysis are listed in Table 1: the median age of the
patients was 68 years, with a range of 47–85 years. Clinical
response to IVC treatment was assessed by screening
parameters of inflammation, cancer markers, complete
blood counts, lipid profiles and nutritional status. The me-
dian follow-up time was 7.2 years and ranged from 1 year
to 18 years.
To analyse the effect of IVC on the level of pro-
inflammatory cytokines, IVC was given to 11 new coming
cancer patients at dose of 15 g, 25 g, 50 g, 50 g, 50 g, and
50 g each time for 6 times. All 11 patients were at relative
clinical stable status after the conventional cancer treat-
ments (surgery, chemo, or radiation therapies). Patients
had different types of cancers (breast, colon, lung, pancre-
atic, renal and prostate cancer). For example, all breast-
cancer patients in the ascorbate-treated group already had
mastectomy and radiotherapy and had been givenhormones, but all had relapsed by the time ascorbate sup-
plementation was commenced. Treatment of this group of
patients was assigned by IVC 15 g-50 g once a day one
time per week. Sera were collected before IVC, before the
6th IVC and after the 6th IVC for the cytokine kit test to
see the trend of IVC effects on cytokines. Six patients were
tested further for the effect of 50 g IVC infusion on C-
reactive protein.
Results
Our database contained forty-five subjects who received
IVC therapy (ranging from one to 100 treatments, with
a median of nine treatments and an inter-quartile range,
IQR, of five to eighteen treatments) and for whom CRP
data were available before or after treatment (Table 1).
Figure 1 shows CRP values before and after treatment.
Most of the subjects, 76 ± 13% (95% confidence)
showed a reduction in CRP values during IVC therapy. If
only subjects who had initially elevated CRP (> 10 mg/L)
levels are considered, 86 ± 13% (95% confidence) showed
a reduction in CRP values during IVC therapy. This
is also indicated by the fact that twenty-eight subjects
had elevated CRP prior to therapy, but only 14 had
elevated CRP levels after treatment. Among the twenty-
eight subjects who started with elevated CRP levels, the
median CPR reduction was 80% with an IQR of 39%
to 94%.
Example of the changed levels of CRP with indicated
periods of IVC treatments by 15 g and 50 g of IVC is
shown in Figure 2.
Unfortunately, our data covers patients who varied in
the number of treatments they received. For patients
with prostate cancer, the percentage decrease in CRP
concentration after treatment was higher when the pa-
tient had more frequent treatments. Median CRP reduc-
tions of 95% were attained in subjects who were treated
frequently (intervals between IVC infusions being fewer
than 10 days) while those treated less frequently. The
negative response to IVC treatment with dosages 15 g-
50 g was found in patients with gastric cancer (CRP was
increased from 1.0 mg/L to 60 mg/L in 160 days, 15
IVC treatments). Progression was measured for three
patients with pancreatic cancer. One patient had metas-
tasis in liver and bones, and for this patient CRP was
increased from 3.8 mg/L to 54 mg/L in 42 days (13 IVC
treatments by dosages 25 g-50 g). For another patient
without metastasis, the increase in CRP was from 2 mg/
L to 25 mg/L in 400 days. The third patient with pancre-
atic cancer had 24 treatments during 90 days and CRP
was increased from 15 mg/L to 89 mg/L. The patient
with cholangiocarcinoma stage IV had 33 IVC treat-
ments in 68 days and CRP was increased from 19 mg/L
to 144 mg/L. Negative outcome was found for a patient
with lung cancer with metastasis. This patient had 37
Table 1 Characteristics of subjects under analysis with duration and number of treatments









Anorectal adenocarcinoma, grade 3, invasive 60 F 19.6 1.9 663 4 low anterior resection,
colorectostomy
Biliary cancer, cholangiocarcinoma S-III(IV) 77 M 19.58 143.76 68 33 No records (NR)
Bladder - transitional cell carcinoma x 2, grade 3 66 M 57.5 11 76 7 operations, post treatment
cycles
Bladder, grade 3 65 M 6.09 0.94 167 7 2 times surgery
Breast 71 M 6.2 3.1 179 2 mastectomy, Tomoxifen
Breast 57 F 19.4 0.4 512 47 NR
Breast 82 F 22 8.9 132 2 radiation, 36 treatments
Breast 66 F 12 2.25 193 3 Lamoxifin - 1.5 year
Breast 89 F 4.1 8.5 454 19 NR
Breast, ductal carcinoma in situ, high
nuclear grade
67 F 21.1 5.5 555 12 no surgery
Breast carcinoma in situ, Basal cell
carcinoma, Lymphoma
71 F 133.2 2.3 682 surgery, mastectomy,
chemotherapy
Breast, category 5 78 F 8.6 13.1 379 20 NR
Breast, poorly differentiated duct cell
carcinoma grade 4,
Pancreas, malignant stage III, nonresectable
78 F 3.7 8.9 233 4 no radiation or chemotherapy,
mastectomy
Breast, infiltrating tubular carcinoma 77 F 2.7 7.9 232 3 no radiation, chemotherapy or
mastectomy
Breast, stage 1, T1 OMO, grade 2 53 F 12 3.8 44 11 lumpectomy
Breast, Stage IIA; Nottingham grade 2 69 F 9.3 3 121 20 breast lumpectomy; partial
mastectomy; excision (L) breast;
Colon, stage IV, liver cancer 64 M 44 3.4 232 12 surgery, chemotherapy,
hepatic resection
Gastric cancer 70 M 1.6 59.8 159 15 NR
Large B cell lymphoma 25 F 10.5 0.3 82 18 NR
Lung 65 M 216 35.9 174 27 NR
Lung - squamous cell, grade 2 80 M 9 6.7 82 20 surgery, no chemotherapy
Lung, renal 82 F 19.2 59 167 37 NR
Lymphoma 53 F 10.8 5.2 110 5 Immune therapy 4 treatments/
week every 6 months, Rutuxin
Pancreas 85 M 3.8 54.5 42 11 NR
Pancreas, breast 71 F 10.1 0.4 119 44 NR
Pancreas, liver and bone metastasis 89 M 2 25 423 cholecystojejunostomy and
gastrojejunostomy
Pros, Gleason score 6-8 82 M 3.9 8.8 279 8 no surgery or hormonal therapy
Prostate 77 M 26.2 0.4 261 16 NR
Prostate 80 M 153.3 148.4 11 5 NR
Prostate 93 M 29.2 2.1 136 20 NR
Prostate, colon cancer 89 M 43.4 31.5 113 5 chemotherapy, colonectomy
Prostate, Gleason score 2.5, malignant
skin melanoma
72 M 6 0.9 140 8 NR
Prostate, Gleason score 6 53 M 8.4 1.9 38 4 surgery
Prostate, Gleason score 6, squamous cell
melanoma, bone cancer
78 M 35.5 1.3 23 4 radical prosectomy
Prostate, Gleason score 6, stage T2A 72 M 22.1 3.66 400 surgery
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Prostate, Gleason score 7 78 M 16.7 4.8 401 4 radiation and hormonal therapy
Prostate, pancreas 74 M 14.9 40.7 89 24 NR
Prostate, pancreas 86 M 500 54.3 542 102 NR
Prostate, stage I 65 M 2.53 8.59 82 1 prostatectomy
Prostate, Gleason score 4, increased to
6–9 during 2 years
81 M 5 0.6 1449 3 NR
Prostate, Esophageal cancer 84 M 15.3 3.1 37 6 removal of esophagus
Prostate, metastatic adenocarcinoma,
Gleason score 4 + 4 = 8
74 M 25 0.7 791 7 radical prostatectomy
Rectal adenocarcinoma, invasive through
muscle layer
71 M 2.2 7.2 137 2 chemotherapy radiation
Renal, Basal cell carcinoma 82 M 30.5 19.5 48 10 operation, 33 treatments
by radiation
Skin, B-cell Lymphoma, Lung 83 M 8.9 1.5 754 36 surgery, 40 radiations
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19 mg/L to 59 mg/L.
Progression was found for 2 patients with breast can-
cer (one with infiltrating tubular carcinoma, poorly dif-
ferentiated duct cell carcinoma with second diagnosis
pancreatic cancer in malignant stage 3, non-resectable),
and another with breast cancer, category 5. For these
patients the increase was mild from 3 mg/L and 8 mg/L
to 10 mg/L and 13 mg/L frequently showed median
CRP reductions of 64%.
The effects of IVC therapy on PSA tumor marker
levels is shown in Figure 3. We had twenty patients for
whom PSA levels were assessed before and after IVCFigure 1 C-reactive protein levels after intravenous vitamin C
treatments are compared to CRP levels before treatments. Data
points (squares) under the diagonal line demonstrate a positive
effect of treatment introducing CRP levels. Data points above the
diagonal indicate CRP increases after treatment.therapy. Fifteen of these subjects, 75% with a 95% confi-
dence interval of ± 19%, showed reduced PSA levels dur-
ing IVC treatment. The examples of the positive
response to IVC treatments for patients with prostate
cancer are presented in Figures 4 and 5.
We also had data from nineteen other subjects (mostly
breast cancer patients, with a few lung, pancreatic, blad-
der, and colon cancer patients) for cancer markers CEA,
CA27.29, or CA15.3. There was statistically no benefit
here, with only 53 ± 22% (95% confidence) of subjectsFigure 2 Tracking of CRP concentration (solid squares and
curve) over time in a 67 year old subject with ductal
carcinoma. The subject was given ten IVC treatments of 15 g (time
of treatment indicated by open squares near the x axis) and eleven
treatments of 50 g (indicated by open circles near the x axis).
Treatments were typically given weekly. CRP concentration
decreased from an initial value of 16 mg/L level to a final value of
5.5 mg/L after the last treatment.
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treatments.
Table 2 summarizes the percentage of patients who
saw improvement in various parameters. The fraction of
subjects seeing reduced inflammation, as measured by
decreases in CRP, was significantly above fifty percent in
the prostate cancer group, the breast cancer group, and
the entire study group. IVC seemed to have a beneficial
effect in reducing PSA levels, but we could not see a sig-
nificant effect in breast cancer subjects or other cancer
markers.
In patients for whom both tumor marker and CRP
data are available, we found an interesting correlation:
patients who had reduced CRP levels tended to also have
reduced tumor marker values. This is shown in Figure 6:
linear regression shows a positive correlation with
r2 = 0.62. Note that we did not observe a correlation be-
tween CRP concentrations and tumor marker values
pre-treatments (r2 = 0.02)
To study the effects of IVC on inflammation in more
detail, we measured serum cytokine levels in eleven sub-
jects before and after IVC therapy. These subjects were
given six treatments (at doses of 15 g for the first treat-
ment, 25 g for the second treatment, and 50 g for the
next four treatments). Plasma ascorbate levels in these
subjects were measured to verify that sufficient concen-
trations were attained for cytokine effects. At the fifty
gram treatments, plasma ascorbate concentrations im-
mediately post infusion reached average values of
roughly 18 mM. The effects of these treatments on
serum concentrations of key pro-inflammatory cytokinesFigure 3 Changes in PSA levels after IVC treatments are
compared to PSA levels before treatments. Data points (squares)
under the diagonal line demonstrate a positive effect of treatment
in reducing PSA levels. Data points above the diagonal line indicate
PSA increases after treatment.are shown in Figure 7. This figure shows two endpoints
for each cytokine. The first is the change in cytokine
concentration at the point just before the patients are
given their sixth IVC dose and after this single 50 g IVC.
The second is the change in cytokine concentration
(relative to pre-therapy value) at the point just after the
patients are given all six IVC dosages. The first endpoint
perhaps indicates sustained reductions in cytokine levels
due to one treatment while the second indicates an ef-
fect of ascorbate after several dosing. After six treat-
ments, patients had noticeably lower levels of IL-2,
TNF-α, and eotaxin. All cytokine levels were reduced
after the last IVC injection. For six of these subjects,
CRP levels were measured before and after the last injec-
tion of IVC. In all six cases, CRP concentrations
decreased, typically by ten percent, after the infusion.Discussion
The vitamin C is used in complementary oncology, with
intravenous administration being of particular interest
since it allows for plasma ascorbate concentrations
an order of magnitude beyond those attainable with oral
administration [62,63]. Clinical studies suggest that
this approach is feasible and potentially beneficial
[47,48,64,65]. Several mechanisms of action for ascor-
bate efficacy against cancer have been proposed over the
years, but to our knowledge its potential role in mediat-
ing inflammation has not been previously addressed. In
the research described in this manuscript, we used CRP
as a clinical inflammation marker. Twenty-eight out of
forty-five subjects in our study had sharply elevated CRP
levels (above 10 mg/L) prior to IVC therapy, suggesting
that inflammation is a prevalent problem for cancer
patients. This is especially important since other reports
indicate that inflammation, particularly elevated CRP, is
a marker of a poor prognosis [66]. In 76 ± 13% of our
subjects, IVC therapy reduced CRP levels, with improve-
ments being more prevalent (86 ± 13%) in the sub-
population with pre-treatment CRP above 10 mg/L.
Post-treatment, the number of subjects with these
sharply elevated CRP levels was reduced from 28 to 14.
We found that decreases in CRP during treatment cor-
related with tumour marker decreases. This is consistent
with other work [67] demonstrating that plasma CRP
levels are well-correlated with serum PSA levels in pros-
tate cancer patients. In the study [67] it was hypothe-
sized that prostatic infection and inflammation may
increase serum prostate-specific antigen levels. In
addition, authors suggest that plasma CRP measure-
ments may help to differentiate benign conditions from
prostate cancer in patients with elevated serum PSA
levels. Inflammation might be fundamental in prostate
cancer and chronic inflammation may be a legitimate
Figure 4 (A, B) – Tracking of PSA levels (circles, squares and curve) over time in two subjects with prostate cancer. Subjects were given
IVC treatments at times indicated by the open squares. Subject A: initial Gleason score = 4; treatments typically given monthly at doses of either
25 g (34 treatments) or 50 g (38 treatments); At maximum PSA values (~ 60 ng/mL) treatments were given weekly. PSA levels decreased from
initial values of 10–60 ng/mL to final values of 1–2.4 ng/mL. Subject B: initial Gleason score = 6–9; treatments typically given weekly at doses of
either 7.5 g (2 treatments) or 25 g (40 treatments); PSA levels decreased from maximum values of 1500 ng/mL to a final value of 7 ng/mL.
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ment. Inflammatory processes also play a role in the de-
velopment of histologic benign prostatic hyperplasia
[68,69]. Acute and chronic inflammatory infiltrates are
routinely found in prostate tissue specimens obtainedFigure 5 (A, B) - Tracking of PSA levels (solid circles and curve) over t
treatments at times indicated by the open squares. Subject A: initial Gleaso
of 25 g; PSA levels decreased from initial values of 60 ng/ml to final values
typically given weekly or twice weekly at doses of either 25 g (140 treatme
and then experienced a steep increase after treatment was discontinued.from men with BPH, and greater levels of inflammation
have been observed in larger prostates [70-73].
It is interesting in our study, therefore, that prostate
cancer patients showed the most benefit (in terms of
reduced PSA and CRP levels) from IVC therapy. Aime in two subjects with prostate cancer. Subjects were given IVC
n score =6; treatments typically given weekly or twice weekly at doses
in the normal range. Subject B: initial Gleason score = 6 – 8; treatments
nts) or 50 g (7 treatments); PSA levels rose and fell during treatments,
Table 2 Percentage of patients who saw reduction in CRP
or tumour marker levels after IVC therapy “ ± ” indicates
95% confidence intervals, “†” indicates proportions
significantly above 50%
Cancer Type N % Improvement
CRP Reduction
Prostate 14 79 ± 21 †
Breast 10 80 ± 25 †
All patients 45 76 ± 13 †
Tumour Marker Reduction
Prostate 18 77 ± 21 †
All PSA 20 75 ± 19 †
Breast 11 73 ± 26
All CA/CEA 19 53 ± 22
All patients 40 65 ± 15 †
Figure 7 Percentage of reduction in serum cytokine levels after
IVC therapy. Data present the changes in the level of
proinflamatory cytokines after treatment by single dosage of 50 g
IVC (pre6/post6) and after 6 treatments by IVC with dosages 15 g-
50 g (pre1/post6). In all cancer patients initial level of vitamin C in
plasma was low (0.9-1.2 mg/dl) and increased to the levels 200–
300 mg/dL after last IVC. In all cases, proinflammatory cytokine levels
decreased during IVC treatment.
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supported by our serum cytokine data, which demon-
strate that levels of pro-inflammatory cytokines decrease
during IVC therapy. IL-2, TNF-α, and eotaxin appeared
to be chronically reduced in patients getting IVC ther-
apy, while all six cytokines studied (IL-1α, IFN-γ, and IL-
8, in addition to IL-2, TNF-α, and eotaxin) were acutely
reduced after ascorbate infusions of 50 g. Average de-
pression of IL-1 was 20% for six patients and the average
decrease for eotaxin was 25%. Interleukin-1 is known to
promote inflammatory processes and augment metasta-
sis [74]. It is abundant at tumour sites, where it affects
the process of carcinogenesis, tumour growth andFigure 6 Correlation between changes in CRP levels and
changes in tumour markers after IVC therapy. Linear regression
indicates a positive correlation (R2 = 0.62) between changes in CRP
and changes in the values of tumour markers PSA and CA 27.29.
Data excluded several cases of aggressive tumours when the
changes in CRP and tumour markers were higher than 300%.invasiveness, and the patterns of tumour-host interac-
tions [75,76]. IL-1 induces uPA expression and NF-kB
activation. TNF-alpha, another key inflammatory cyto-
kines, plays a central role in the tumour progression.
Constitutive expression of the TNF-alpha from tumour
microenvironment is a characteristic of many malignant
tumours and its presence is often associated with poor
prognosis [77-80]. Eotaxin-1 (CLL11) is a chemo-
attractant and lymphocyte activator that has been shown
to affect tumour cell growth [81-83]. Chemokine recep-
tor expression in many cancers correlates with poor
prognosis, and there is evidence that eotaxin induces
angiogenesis and metastasis [84].
In summary, our analysis of data from cancer
patients given IVC, along with our tests of cytokine
levels, suggest that IVC may reduce inflammation in
cancer patients, and that this reduction in inflamma-
tion is correlated with reductions in the tumour mar-
kers PSA.
The strength of the study is that we used the protocol
established in our clinic for the treatment of cancer
patients by IVC therapy, lacking at many clinics at least
as adjuvant therapy in treatment of malignant disease,
and demonstrated the effect of this treatment on the
level of inflammation in cancer patients. We analysed
the array of patients with various forms of malignant
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malignancies than other forms of malignant disease.
The limitations of the study are that the measurements
of parameters of inflammation and tumour markers
were not very detailed and many patients did not have
measurements of the inflammation cytokines during
treatment.
Further research in this area and clinical studies of the
efficacy of intravenous high dose vitamin C are warranted.
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